Rickettsialpox (MONDO:0019360): A Comprehensive Disease Characteristics Report

Summary

Rickettsialpox is a mild, self-limited febrile spotted fever group (SFG) rickettsiosis caused by the obligate intracellular bacterium Rickettsia akari, transmitted to humans by the bite of the house-mouse mite Liponyssoides sanguineus, whose natural reservoir is the common house mouse (Mus musculus). It is an infectious, non-heritable urban zoonosis first described in New York City in 1946 and remains endemic there today. After an incubation period of roughly 9–14 days, patients develop a painless inoculation eschar at the mite-bite site, followed by abrupt fever, headache, chills, myalgia, and regional lymphadenopathy, and then a generalized papulovesicular ("chickenpox-like") rash. The illness resolves over 2–3 weeks, systemic complications (e.g., self-limited hepatitis) are rare, and no deaths have been attributed to the disease.

The pathophysiology is shared across the spotted fever group: R. akari invades vascular endothelial cells, damaging them directly, increasing vascular permeability, and producing a small-vessel lymphohistiocytic vasculitis that underlies both the local eschar and the disseminated rash. Diagnosis relies on the clinical triad (eschar + fever + papulovesicular rash), skin-biopsy immunohistochemistry demonstrating SFG rickettsiae, indirect immunofluorescence serology (a four-fold IgG rise or a single titer ≥1:64), and increasingly on PCR of eschar or lesion material (gltA, ompA, ompB, 17-kDa genes). Empiric doxycycline is curative and produces rapid defervescence; the prognosis is excellent.

Because rickettsialpox is not a nationally notifiable disease in the United States, it is widely under-diagnosed and under-reported; reported incidence tracks clinician awareness rather than true disease burden. Prevention is entirely environmental — rodent population control, mite/vector control with acaricides, and improved dwelling sanitation. There is no vaccine, no genetic susceptibility component, and no Mendelian OMIM/Orphanet entry, because the disease is infectious rather than heritable. Serologic evidence of R. akari exposure in urban dogs and cats supports a One Health, urban-rodent ecology and a broader geographic footprint than the classic New York foci.

This report is organized against the 15-section disease-characteristics template. Sections tied to genetic disease (causal genes, pathogenic variants, inheritance, model organisms of a heritable condition) are explicitly marked Not applicable because rickettsialpox is an acquired infection.

Key Findings

Finding 1 — Etiology: Rickettsia akari transmitted by the house-mouse mite

Rickettsialpox is caused by Rickettsia akari, an obligate intracellular, Gram-negative bacterium of the spotted fever group, and is transmitted to humans by the bite of the mite Liponyssoides sanguineus (formerly Allodermanyssus sanguineus), which infests the common house mouse Mus musculus. The causal chain — agent, vector, reservoir — is well established in primary literature. As stated directly: "Rickettsialpox is an acute, self-limited, febrile illness caused by Rickettsia akari and transmitted by Liponyssoides sanguineus, a mite that infests the common house mouse, Mus musculus" PMID: 18171106.

Serologic and immunohistochemical confirmation of R. akari as the etiologic agent in human cases was documented in a consecutive New York City hospital case series: "A 4-fold or greater increase in IgG antibody titers reactive with Rickettsia akari was observed in all 9 patients for whom acute and convalescent phase samples were available" PMID: 14676069. Because transmission is mite-borne rather than tick-borne, rickettsialpox is unusual among SFG rickettsioses; the mite vector both maintains the organism transovarially and delivers it during blood feeding.

Evidence type: human clinical / serologic (aggregated case series). Organism terms: Rickettsia akari (NCBITaxon:786); Mus musculus (NCBITaxon:10090); vector Liponyssoides sanguineus.

Finding 2 — Clinical presentation and endemic urban persistence

Rickettsialpox presents as a self-limited febrile illness defined by two hallmark skin lesions: an inoculation eschar and a generalized papulovesicular rash. In a consecutive NYC series of 18 patients (2001–2002), immunohistochemistry detected SFG rickettsiae in the great majority of lesions: "Immunohistochemical testing revealed spotted fever group rickettsiae in all 16 eschars and in 5 of the 9 papulovesicles tested" PMID: 14676069. The disease is clinically important because it mimics more dangerous conditions: "Rickettsialpox is a self-limited febrile illness with skin lesions that may be mistaken for signs of potentially more serious diseases, such as cutaneous anthrax or chickenpox" PMID: 14676069. Notably, 50% of that series presented in the five months after the October 2001 anthrax bioterrorism events, indicating that heightened clinician awareness — not a true rise in incidence — drove detection.

Systemic complications are uncommon but recognized; self-resolving hepatitis has been reported: "we describe two patients with rickettsialpox who had acute hepatitis that resolved completely" PMID: 18171106.

Evidence type: human clinical case series.

Finding 3 — Pathophysiology: endothelial invasion and small-vessel vasculitis

The core pathophysiology is shared with the entire spotted fever group. In David Walker's authoritative SFG review, "These obligate intracellular bacteria invade vascular endothelial cells, which are damaged directly, causing increased vascular permeability" PMID: 2677080, and an eschar forms at the site of the vector bite. Mechanistic studies of related SFG rickettsiae (R. conorii, R. parkeri) confirm the shared pathogenic program that is inferred to apply to R. akari: preferential tropism for microvascular endothelium producing barrier dysfunction and increased permeability. "Obligate intracellular bacteria which exhibit preferential tropism for host microvascular endothelium in the mammalian hosts, resulting in disease manifestations attributed primarily to endothelial damage or dysfunction" PMID: 32977742; and "vascular inflammation and dysfunction represent salient features of rickettsial pathogenesis" PMID: 33003310.

Downstream molecular events characterized in SFG models include mTOR (mTORC1/mTORC2) activation in infected human endothelial cells PMID: 33003310, and endothelial secretome/exosome changes that drive barrier dysfunction and edema PMID: 31955791, PMID: 33975935.

Evidence type: authoritative review (human) + in vitro/in vivo mechanistic studies of related SFG species (inferred to R. akari).

Finding 4 — Diagnosis and curative treatment

Diagnosis relies on serology and biopsy immunohistochemistry, and empiric doxycycline is curative. Per Walker: "Rickettsiae are demonstrable by diagnostic immunohistology in biopsies of rash or eschar. Empiric treatment with doxycycline, tetracycline, or chloramphenicol should be given early in the course on the basis of clinical suspicion" PMID: 2677080. The NYC series demonstrated diagnosis by IHC of paraffin-embedded skin biopsy (SFG rickettsiae in 16/16 eschars and 5/9 papulovesicles) and by indirect immunofluorescence serology (four-fold IgG rise or single titer ≥1:64) PMID: 14676069. Serology cross-reacts broadly across the SFG (e.g., R. rickettsii antigen can be used as a screen). Rickettsialpox is self-limited even without treatment, with no reported deaths, and doxycycline produces rapid resolution.

Evidence type: authoritative review + human case series.

Finding 5 — One Health ecology: animal seroreactivity

Urban companion animals show measurable R. akari seroreactivity, supporting a One Health, urban-rodent ecology and a broad geographic distribution. In New York City dogs, "Cross-absorption testing indicated that in 6 of 7 samples, infection was caused by R akari. Results suggest that dogs can be naturally infected with R akari" PMID: 11394829; 7.7% of 311 dogs were EIA-positive for SFG rickettsiae, with tick infestation and increasing age as significant risk factors. Among 170 US cats, seroprevalence was "14.9% for R akari" PMID: 16434226. Human SFG seroreactivity including R. akari was also detected in a Papua New Guinea serosurvey PMID: 16450784, indicating exposure beyond the classic foci.

Evidence type: veterinary/human seroepidemiology.

Finding 6 — Clinical course and natural history

The classic natural history is a ~9–14 day incubation, a painless inoculation eschar, then fever/headache and a generalized papulovesicular rash resolving over 2–3 weeks. A mite bite produces a painless papule that becomes a vesicle and then a black-crusted eschar (IHC-positive in 16/16 eschars in the Koss series) PMID: 14676069. After incubation, patients develop abrupt fever, chills, headache, myalgia, and often regional lymphadenopathy, followed within 2–3 days by a generalized papulovesicular eruption (IHC-positive in 5/9 papulovesicles). Eschar formation at the vector inoculation site is a defining SFG feature: "Eschar occurs in some SFG rickettsioses at the site of tick bite" PMID: 2677080. The illness is acute and self-limited; systemic complications are rare (occasional self-resolving hepatitis) PMID: 18171106.

Finding 7 — Epidemiology and prevention: under-reported urban zoonosis

Rickettsialpox is not nationally notifiable in the US and is regarded as under-diagnosed and under-reported; reported incidence tracks clinician awareness. The NYC authors concluded: "Rickettsialpox remains endemic in New York City, and the bioterrorism attacks of October 2001 may have led to increased awareness and detection of this disease" PMID: 14676069. The disease occurs where humans contact the rodent-associated mite: "The hematophagic-biting mite, Liponyssoides sanguineus, is a mite of the rat, mouse, and other domestic rodents but can also bite humans" PMID: 17114713, with ectoparasite exposure heightened in homeless and inner-city populations. Prevention is achieved through rodent population control, mite/vector control (acaricides), and improved sanitation.

Finding 8 — Identifiers and classification

Rickettsialpox is classified as an infectious spotted fever group rickettsiosis, not a genetic disease. Phylogenetic analysis of the citrate synthase (gltA) gene places the mite-borne organism within the SFG cluster: "the mite-borne organism Rickettsia akari were associated with the SFG cluster" PMID: 9103608. Standard identifiers: MONDO:0019360; ICD-10 A79.1 (Rickettsialpox due to Rickettsia akari); MeSH D012288; pathogen NCBITaxon:786. There is no OMIM or Orphanet Mendelian entry because the disease is infectious. Synonyms include vesicular rickettsiosis and Kew Gardens spotted fever.

Report by Template Section

1. Disease Information

Overview. Rickettsialpox is an acute, mild, self-limited febrile illness caused by Rickettsia akari and transmitted by the mite Liponyssoides sanguineus PMID: 18171106. It is characterized by an inoculation eschar and a disseminated papulovesicular rash, and it resolves without sequelae.

Key identifiers. MONDO:0019360; ICD-10 A79.1; MeSH D012288 (Rickettsialpox); pathogen taxon NCBITaxon:786 (Rickettsia akari). No OMIM or Orphanet entry (non-heritable, infectious disease).

Synonyms / alternative names. Vesicular rickettsiosis; Kew Gardens spotted fever; Rickettsia akari infection.

Information source. Derived predominantly from aggregated disease-level resources and hospital case series (e.g., the New York City consecutive series, 14676069) plus authoritative SFG reviews — not individual EHR-level datasets.

2. Etiology

• Causal factor (infectious): Rickettsia akari, an obligate intracellular SFG bacterium PMID: 18171106, PMID: 14676069.
• Vector: the house-mouse mite Liponyssoides sanguineus PMID: 18171106, PMID: 17114713.
• Reservoir: the common house mouse Mus musculus PMID: 18171106.
• Genetic risk factors: None identified. No human susceptibility loci, GWAS signals, or modifier genes are known; this is an acquired infection.
• Environmental risk factors: residence in or exposure to mouse-infested dwellings, crowded urban housing, and inner-city/homeless settings with heightened ectoparasite exposure PMID: 14676069, PMID: 17114713.
• Protective factors: rodent and mite control; sealing dwellings; sanitation. No genetic protective variants known.
• Gene–environment interactions: Not applicable (no genetic component).

3. Phenotypes

Onset: adult-onset in most reported cases (exposure-dependent, any age). Severity: mild to moderate. Progression: acute, self-limited, resolving over 2–3 weeks. Quality-of-life impact: minimal and transient; full recovery is the norm.

4. Genetic / Molecular Information

Not applicable. Rickettsialpox is an infectious disease with no causal human genes, pathogenic variants, modifier genes, epigenetic drivers, or chromosomal abnormalities. Molecular characterization pertains to the pathogen genome (SFG classification by gltA/citrate synthase phylogeny PMID: 9103608), not the host.

5. Environmental Information

• Environmental factors: proximity to house-mouse populations and their mites in urban dwellings PMID: 17114713.
• Lifestyle factors: living conditions with rodent infestation; inner-city/homeless exposure PMID: 17114713.
• Infectious agent: Rickettsia akari (NCBITaxon:786), an obligate intracellular SFG bacterium PMID: 18171106.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Infected mite (Liponyssoides sanguineus) bites human skin
     └─ inoculates R. akari into the dermis
        ↓ leads to
2. R. akari attaches to and invades local vascular endothelial cells
   (obligate intracellular replication)
        ↓ results in
3. Direct endothelial cell damage + local dermal infection/necrosis
        ↓ leads to
4. Formation of the inoculation ESCHAR at the bite site
        │
        ├─ (branch, local) eschar = tache noire
        │
        ↓ concurrently, hematogenous / lymphatic dissemination
5. Systemic seeding of microvascular endothelium in skin and organs
        ↓ leads to
6. Endothelial barrier dysfunction + increased vascular permeability
   (mTORC1/2 activation; secretome/exosome changes — shown in SFG models,
    inferred for R. akari)
        ↓ results in
7. Small-vessel LYMPHOHISTIOCYTIC VASCULITIS
        ↓ produces
8. Clinical manifestations: fever, headache, myalgia, lymphadenopathy,
   and the disseminated PAPULOVESICULAR RASH
        │
        └─ (rare branch) hepatic endothelial involvement → self-limited hepatitis

• Upstream events: mite inoculation and endothelial invasion (steps 1–2).
• Downstream events: vasculitis, permeability, rash and systemic symptoms (steps 6–8).
• Cell types (CL): vascular endothelial cell (CL:0000115); macrophage/histiocyte and lymphocyte infiltrates in the perivascular lymphohistiocytic reaction.
• Biological processes (GO): GO:0044409 (entry into host); regulation of vascular permeability; inflammatory response; GO:0031929 (TOR signaling).
• Molecular pathways: mTOR (mTORC1/mTORC2) activation in infected endothelium PMID: 33003310.
• Immune involvement: perivascular lymphohistiocytic infiltration; innate and T-cell responses control rickettsial propagation (illustrated in the R. parkeri benidipine model, where impaired Ca²⁺/innate signaling converted sublethal to lethal infection PMID: 38408129).
• Proteomic/secretome markers: the rickettsial protein RC0497 (putative N-acetylmuramoyl-L-alanine amidase) is secreted into the endothelial secretome and circulates during SFG infection PMID: 31955791; endothelial exosomes contribute functionally to infection PMID: 33975935.

Note: Steps 6–7's molecular detail is demonstrated primarily in related SFG species (R. conorii, R. parkeri) and is inferred to apply to R. akari, which shares the endothelial-tropism program PMID: 2677080, PMID: 32977742.

7. Anatomical Structures Affected

• Primary organ/tissue: skin (UBERON:0002097), at the eschar and across the papulovesicular rash.
• Vascular system: small blood vessels / microvasculature (UBERON:0001981) — the primary target through endothelial infection.
• Secondary organ involvement: liver (UBERON:0002107) in rare hepatitis PMID: 18171106; regional lymph nodes (UBERON:0000029).
• Body systems: integumentary and cardiovascular (microvascular); reticuloendothelial (lymphadenopathy).
• Cell level: vascular endothelial cells (CL:0000115) are the primary infected cell; perivascular macrophages/histiocytes and lymphocytes constitute the inflammatory infiltrate.
• Subcellular (GO cellular component): cytoplasm of endothelial cells (obligate intracellular replication); host plasma membrane at entry.
• Localization / lateralization: eschar is typically solitary and unilateral at the bite site; the rash is generalized/bilateral.

8. Temporal Development

• Incubation: ~9–14 days from mite bite to systemic symptoms PMID: 14676069.
• Onset pattern: eschar develops first (subacute local lesion), then abrupt/acute onset of fever and constitutional symptoms; rash follows within 2–3 days.
• Progression: self-limited; resolves over ~2–3 weeks.
• Course: monophasic, non-relapsing; no chronic phase.
• Remission: spontaneous (even untreated) and accelerated by doxycycline.
• Critical intervention window: early empiric doxycycline shortens symptomatic course; because the disease is benign, timing is less critical than in Rocky Mountain spotted fever, but early treatment remains standard PMID: 2677080.

9. Inheritance and Population

• Inheritance: Not applicable — infectious, non-heritable. No penetrance, expressivity, anticipation, mosaicism, founder-effect, consanguinity, or carrier-frequency parameters apply.
• Epidemiology: under-reported; not nationally notifiable in the US. Endemic in urban New York City and reported in other urban centers and internationally (seroepidemiologically in additional regions) PMID: 14676069, PMID: 16450784. Precise prevalence/incidence figures are unreliable due to under-diagnosis.
• Geographic distribution: worldwide wherever the house mouse and its mite coexist with humans; classically urban.
• Demographics: linked to mouse-infested housing; heightened exposure in crowded inner-city and homeless populations PMID: 17114713. No strong intrinsic sex or ethnic predisposition beyond exposure differences.

10. Diagnostics

• Clinical criteria: the triad of eschar + fever + papulovesicular rash with a compatible exposure history.
• Histopathology/IHC (confirmatory): immunohistochemistry of eschar or papulovesicle biopsy detects SFG rickettsiae (16/16 eschars, 5/9 papulovesicles) PMID: 14676069; biopsy immunohistology is the gold-standard tissue confirmation per Walker PMID: 2677080.
• Serology (IFA): four-fold IgG rise or single titer ≥1:64 reactive with R. akari; useful mainly in convalescence and cross-reactive across SFG PMID: 14676069, PMID: 2677080.
• Molecular (PCR): amplification/sequencing of gltA, ompA, ompB, and 17-kDa antigen genes from eschar/lesion material identifies and speciates SFG rickettsiae; gltA phylogeny confirms R. akari within SFG PMID: 9103608.
• Laboratory findings: may include mild transaminase elevation in hepatitis cases PMID: 18171106.
• Genetic/omics testing: Not applicable to host diagnosis.
• Differential diagnosis: chickenpox (varicella), cutaneous anthrax, other SFG rickettsioses, disseminated herpes, and vesicular eruptions PMID: 14676069.

11. Outcome / Prognosis

• Mortality: ≈0%; no deaths attributed to rickettsialpox PMID: 14676069, PMID: 2677080.
• Morbidity: low; illness is self-limited with full recovery.
• Complications: rare, notably self-resolving hepatitis PMID: 18171106.
• Recovery: complete, with or without antibiotics; doxycycline accelerates resolution.
• Prognostic factors: benign regardless; prompt doxycycline shortens symptom duration.

12. Treatment

Empiric doxycycline should be started early on clinical suspicion and produces rapid defervescence PMID: 2677080. No gene, cell, RNA, or immunotherapy is relevant. No pharmacogenomic modifiers are established. Supportive care (antipyretics) is adjunctive. Because the disease is self-limited, treatment mainly shortens symptomatic duration.

13. Prevention

• Primary prevention (environmental): rodent population control, mite/vector control with acaricides, sealing and sanitizing dwellings to eliminate house-mouse infestation PMID: 17114713, PMID: 18171106.
• Secondary prevention: clinician awareness and prompt recognition/treatment; enhanced surveillance (the disease is under-reported) PMID: 14676069.
• Immunization: None — no vaccine exists.
• Public health: integrated urban rodent/ectoparasite control and health education; One Health surveillance including companion-animal sentinels PMID: 11394829.
• Genetic screening / counseling: Not applicable.

14. Other Species / Natural Disease

• Reservoir host: house mouse Mus musculus (NCBITaxon:10090); the vector is the mite Liponyssoides sanguineus PMID: 18171106.
• Companion-animal exposure (sentinels): dogs — natural R. akari infection confirmed by cross-absorption (6/7 samples) with 7.7% SFG seropositivity in 311 NYC dogs PMID: 11394829; cats — 14.9% R. akari seroprevalence among 170 US cats PMID: 16434226.
• Zoonotic potential: rickettsialpox is inherently a zoonosis (rodent reservoir, mite vector, human incidental host).
• Comparative biology: endothelial-tropism pathogenesis is conserved across SFG rickettsiae in mammalian hosts PMID: 2677080, PMID: 32977742.

15. Model Organisms

Because rickettsialpox is infectious, "model organisms" refer to infection models, not genetic disease models. Murine models of SFG rickettsiosis (e.g., R. conorii and R. parkeri in mice) recapitulate endothelial infection, vascular permeability, and disease severity, and have been used to test mechanistic interventions — for example, the calcium-channel blocker benidipine converted sublethal to lethal R. parkeri infection by impairing innate immunity PMID: 38408129. Primary human umbilical vein endothelial cells (HUVEC) serve as the standard in vitro model for endothelial infection, secretome, and mTOR signaling studies PMID: 31955791, PMID: 33003310. These models capture the shared SFG endothelial pathogenesis but are largely developed for more virulent species; R. akari-specific models are sparse, and its intrinsically mild phenotype limits severity-focused modeling.

Mechanistic Model / Interpretation

The disease can be read as a single mechanistic story with one local branch and one systemic branch, both flowing from a single lesion — endothelial infection.

The unifying insight is that R. akari is a comparatively avirulent member of a virulent family. It uses the same endothelial-tropism program as R. conorii and R. rickettsii — invade endothelium, damage it, increase vascular permeability, trigger small-vessel vasculitis — but produces a mild, self-limited disease with near-zero mortality. The clinical hallmarks (eschar + papulovesicular rash) map directly onto the local and systemic branches of endothelial infection. This makes rickettsialpox both a diagnostic mimic (chickenpox, cutaneous anthrax) and an informative "benign end" of the SFG severity spectrum.

Evidence Base

Evidence types span human clinical case series (14676069, 18171106), authoritative reviews (2677080), in vitro/in vivo mechanistic studies of related SFG species (32977742, 33003310, 31955791, 33975935, 38408129), seroepidemiology (11394829, 16434226, 16450784), and molecular phylogeny (9103608).

Limitations and Knowledge Gaps

1. Mechanistic detail is inferred, not R. akari-specific. The endothelial-invasion, permeability, mTOR, secretome, and exosome findings come from R. conorii/R. parkeri models. While the shared SFG program strongly supports extrapolation, direct R. akari molecular studies are sparse.
2. Epidemiology is unreliable. The disease is not notifiable and is under-diagnosed; no dependable prevalence/incidence rates exist, and reported case counts track awareness (e.g., the post-2001 detection spike).
3. Case-series bias. Much of the human clinical data derives from a single NYC hospital series, limiting generalizability of phenotype frequencies.
4. Sparse international quantitative data. Global distribution is supported qualitatively and serologically, but few systematic surveys quantify burden outside New York.
5. No modern therapeutic trials. Treatment recommendations rest on decades of clinical experience and reviews rather than randomized trials (ethically unnecessary given benignity, but formally a gap).
6. Not-applicable sections. Genetic, inheritance, and pharmacogenomic sections are empty by nature; this is correct for an infection, not a data deficiency.

Proposed Follow-up Experiments / Actions

1. Direct R. akari endothelial-infection studies. Perform transcriptomic/proteomic and mTOR-pathway characterization in HUVEC infected with R. akari to confirm (rather than infer) the shared SFG mechanism and to explain its low virulence.
2. RC0497 (or ortholog) as a rapid diagnostic. Test whether the R. akari homolog of the secreted amidase RC0497 PMID: 31955791 is detectable in acute rickettsialpox sera to enable early, species-agnostic point-of-care diagnosis.
3. PCR/next-gen sequencing standardization. Validate a multiplex gltA/ompA/ompB/17-kDa PCR panel on eschar swabs and lesion capillary blood for early confirmation, reducing reliance on convalescent serology.
4. Sentinel surveillance via companion animals. Use canine/feline seroprevalence as an early-warning sentinel for urban R. akari activity and to map geographic footprint PMID: 11394829, PMID: 16434226.
5. Burden quantification. Conduct multi-city seroprevalence surveys in humans in housing with documented mouse infestation to estimate true incidence and correct for under-reporting.
6. Vector-control evaluation. Prospectively measure the effect of integrated rodent + acaricide interventions on human case counts in endemic urban zones.

Report compiled from an autonomous 5-iteration investigation: 8 confirmed findings, 46 papers reviewed. Rickettsialpox is treated throughout as an infectious, non-heritable zoonosis; genetic/inheritance template sections are marked Not Applicable accordingly.